Rezolute

Canaccord Genuity Acted as a Joint Placement Agent in a Private Placement for Rezolute, Inc.

Rezolute, Inc. (the “Company”) (OCTQB:RZLT), announced a $41 million private placement on October 9, 2020 led by CAM Capital with Federated Hermes Kaufmann, Surveyor Capital (a Citadel company) and BVF Partners participating, among others.

The Company issued an aggregate of approximately 124 million shares of common stock at a price per share of $0.33. Each share to be issued will be accompanied by a warrant to purchase 0.33 shares of its common stock at an exercise price of $0.39.

Proceeds from this raise will be used to: (i) advance the Company’s lead asset, RZ358, through Phase 2b clinical development in congenital hyperinsulinism (CHI) in the U.S. and Europe, (ii) initiate a Phase 1 study in the U.S. for the Company’s plasma kallikrein inhibitor, RZ402, for diabetic macular edema, and (iii) fund general corporate purposes including a near-term up-listing to Nasdaq.

Rezolute is advancing targeted therapies for rare, metabolic, and life-threatening diseases. Its lead clinical asset, RZ358, is in Phase 2b development as a potential treatment for CHI, a rare pediatric endocrine disorder. Its pipeline also includes RZ402, an IND-ready orally available plasma kallikrein inhibitor, which is staged to transition into clinical development for the treatment of diabetic macular edema.

Canaccord Genuity acted as a joint placement agent to the Company. The Canaccord Genuity team included Eugene Rozelman, Jennifer Pardi, Brian O’Connor, Mike Wright, Gaurav Mehta, Shawn Zamani, Tyler Chamberland, Esther Lee, Brooke Szczygiel, and Anusha Kavuru.